Penumbra (PEN) risk factors, FY2024 10-K

Business Risks

1. 01Our existing products may be rendered obsolete and we may be unable to effectively introduce and market new products or may fail to keep pace with advances in technology
2. 02We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations
3. 03We may not be able to achieve or maintain satisfactory pricing and margins for our products
4. 04We may not have the resources to successfully market and sell our products, which would adversely affect our business and results of operations
5. 05Third-party reimbursement may not be available or adequate for the procedures or sessions for which our products are used, and may be subject to change
6. 06We have generated a significant portion of our revenue and revenue growth from a limited number of product families, and our revenue and business prospects would be adversely affected if sales of any of these product families were to decline
7. 07significant decline in our sales of any of these product families could also negatively impact our financial condition and our ability to conduct product development activities, and therefore negatively impact our business prospects
8. 08Our dependence on key suppliers puts us at risk of interruptions in the availability of our products, which could reduce our revenue and adversely affect our results of operations
9. 09We cannot be certain that we will be able to manufacture our products in high volumes at commercially reasonable costs
10. 10We are required to maintain high levels of inventory, which consume a significant amount of our working capital and could lead to permanent write-downs or write-offs of our inventory
11. 11Defects or failures or alleged defects or failures associated with our products could lead to recalls, safety alerts, or product-related or securities litigation, as well as significant costs and negative publicity
12. 12Our products are continually the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, which could materially adversely affect our business, financial condition and results of operations
13. 13Negative publicity regarding our products or marketing tactics by competitors or other third parties could reduce demand for our products, which would adversely affect sales and our financial performance
14. 14Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovative approach, creativity, and teamwork fostered by our culture, and our business may be harmed
15. 15To successfully market and sell our products internationally, we must address a number of unique challenges applicable to international markets
16. 16We rely on our distributors to market and sell our products in certain international markets
17. 17Foreign currency exchange rates may adversely affect our results
18. 18We have experienced rapid growth in recent periods, and if we fail to manage our growth effectively, our business and results of operations may suffer
19. 19We depend on key personnel to operate our business and develop our products, and if we are unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed
20. 20We depend on information technology systems to operate our business, and issues with maintaining, upgrading or implementing these systems, could have a material adverse effect on our business
21. 21Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and ability to achieve or maintain profitability

Regulatory Risks

1. 22We are subject to stringent domestic and foreign medical device regulations, which may impede the approval or clearance process for our products, hinder our development activities and manufacturing processes and, in some cases, result in the recall or seizure of previously approved or cleared products
2. 23If we modify our FDA cleared products, we may need to seek and obtain new clearances, which, if not granted, would prevent us from selling our modified products or require us to redesign our products
3. 24We may not receive necessary foreign regulatory approvals or clearances or otherwise comply with foreign regulations
4. 25We may not be able to meet regulatory quality requirements applicable to our manufacturing process
5. 26We are subject to federal, state and foreign healthcare laws and regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future
6. 27If we are found to have improperly promoted our products for off-label uses, we may become subject to significant fines and other liability

Risks Related to Our Intellectual Property

1. 28We rely on a variety of intellectual property rights, and if we are unable to maintain or protect our intellectual property, our business and results of operations will be harmed
2. 29We may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful
3. 30Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties
4. 31Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products
5. 32Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 33If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
7. 34If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed

Risks Related to Our Finances and Capital Requirements

1. 35We may require additional financing in the future and may not be able to obtain such financing on favorable terms, if at all, which could force us to delay, reduce or eliminate our research and development activities or otherwise harm our business
2. 36By engaging in acquisitions and other business development arrangements, we will incur a variety of costs and may potentially face numerous risks that could adversely affect our business and operations
3. 37Fluctuations in our effective tax rate and changes to tax laws may adversely affect us

Risks Relating to Securities Markets and Investment in Our Common Stock

1. 38The price of our common stock may be volatile, and you could lose all or part of your investment
2. 39If our executive officers, directors and largest stockholders choose to act together, they may be able to significantly influence our management and operations, acting in their own best interests and not necessarily those of other stockholders
3. 40A sale of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
4. 41Techniques employed by short sellers have in the past and may in the future drive down the market price of our common stock
5. 42Our restated certificate of incorporation, our second amended and restated bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management
6. 43We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment
7. 44An additional valuation allowance against our deferred tax assets could require a charge to earnings, which could result in a negative impact on our results of operations
8. 45We cannot guarantee we will make any additional repurchases of our common stock under our share repurchase program or otherwise
9. 46It is difficult to forecast future performance, which may cause our financial results to fluctuate unpredictably
10. 47We are exposed to the risk of nonpayment by our customers, which could adversely affect our financial condition or results of operations
11. 48Natural disasters and other events beyond our control could harm our business
12. 49Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results
13. 50Our operations are subject to environmental, health and safety, and data privacy laws and regulations, compliance with which may be costly
14. 51We incur significant costs and devote substantial management time as a result of operating as a public company
15. 52If we fail to maintain an effective system of disclosure controls and procedures and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired
16. 53expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight
17. 54If securities or industry analysts publish inaccurate or unfavorable research about our business or cease publishing research, our stock price and trading volume could decline